Skip to main content

Table 1 Patient and tumor characteristics

From: Dose-escalated salvage radiotherapy after radical prostatectomy in high risk prostate cancer patients without hormone therapy: outcome, prognostic factors and late toxicity

  Group A Group B Group C Total
Factor 66 Gy > 66 Gy < 70 Gy ≥ 70 Gy  
  n =23 (%) n = 15 (%) n = 38 (%) N = 76 (%)
Age:     
   < 60 years 10(43.5) 4(26.7) 10(26.3) 24(31.6)
   ≥ 60 years 13(56.5) 11(73.3) 28(73.7) 52(68.4)
Median     63
Preoperative PSA:     
   ≤ 10 ng/ml 10(43.5) 9(60) 22(57.9) 41(53.9)
   >10 ng/ml ≤ 20 ng/ml 7(30.4) 4(26.7) 10(26.3) 21(27.7)
   > 20 ng/ml 2(8.7) 0(0) 4(10.5) 6(7.9)
Missing 4(17.4) 2(13.3) 2(5.3) 8(10.5)
Median     7,9
Tumor size:     
   pT2 8(34.8) 9(60) 19(50) 36(47.3)
   pT3a 8(34.8) 3(20) 12(31.6) 23(30.3)
   pT3b 6(26.1) 3(20) 7(18.4) 16(21.1)
Missing 1(4.3) 0(0) 0(0) 1(1.3)
Gleason score:     
   ≤ 6 4(17.4) 1(6.7) 2(5.3) 7(9.2)
   7 13(56.6) 9(60) 23(60.5) 45(59.2)
    8 5(21.7) 5(33.3) 13(34.2) 23(30.3)
Missing 1(4.3) 0(0) 0(0) 1(1.3)
Surgical margin:     
   R1 9(39.1) 5(33.3) 17(44.7) 31(40.7)
   Rx (close) 4(17.4) 3(20) 9(23.7) 16(21.1)
   R0 8(34.8) 7(46.7) 10(26.3) 25(32.9)
Missing 2(8.7) 0(0) 2(5.3) 4(5.3)
Risk groups:     
   High 17(73.9) 13(86.7) 33(86.8) 63(82.9)
Intermediate 6(26.1) 2(13.3) 5(13.2) 13(17.1)
Pre-irradiation PSA:     
   ≤ 0.5 ng/ml 15(65.2) 9(60) 22(57.9) 46(60.5)
   > 0.5 ng/ml 8(34.8) 6(40) 16(42.1) 30(39.5)
Median     0,5
Evidence of local recurrence     
   Yes 2(8.7) 2(13.3) 17(44.7) 21(27.6)
   No 21(91.3) 13(86.7) 21(55.3) 55(72.4)